QUEST DIAGNOSTICS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.3 USD | -0.86% |
|
+4.53% | -2.63% |
| Apr. 25 | Labcorp beats quarterly estimates on strong testing demand | RE |
| Apr. 24 | Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 | MT |
Financials (USD)
| Sales 2024 * | 9.45B | Sales 2025 * | 9.75B | Capitalization | 15.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 894M | Net income 2025 * | 960M | EV / Sales 2024 * | 2.02 x |
| Net Debt 2024 * | 4.07B | Net Debt 2025 * | 3.44B | EV / Sales 2025 * | 1.9 x |
| P/E ratio 2024 * |
17.3
x | P/E ratio 2025 * |
15.9
x | Employees | 44,000 |
| Yield 2024 * |
2.13% | Yield 2025 * |
2.2% | Free-Float | 68.19% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quest Diagnostics Incorporated
More recommendations
More press releases
More news
| 1 day | -0.86% | ||
| 1 week | +3.21% | ||
| Current month | +0.86% | ||
| 1 month | +2.44% | ||
| 3 months | +3.80% | ||
| 6 months | +5.15% | ||
| Current year | -2.63% |
1 week
128.38
138.91
1 month
125.42138.91
Current year
123.04143.63
1 year
119.59145.58
3 years
119.59174.16
5 years
73.02174.16
10 years
54.90174.16
| Managers | Title | Age | Since |
|---|---|---|---|
James Davis
CEO | Chief Executive Officer | 61 | 13-03-31 |
Sam Samad
DFI | Director of Finance/CFO | 54 | 22-07-10 |
Kristin Wallace
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Denise Morrison
BRD | Director/Board Member | 70 | 19-02-17 |
Timothy Ring
BRD | Director/Board Member | 66 | 11-12-06 |
Gail Wilensky
BRD | Director/Board Member | 80 | 96-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.84% | 215 M€ | +10.68% | - | |
| 2.17% | 2 M€ | +6.77% | ||
| 2.05% | 8 M€ | +2.44% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 134.3 | -0.86% | 601,735 |
| 24-04-25 | 135.4 | -1.55% | 1,016,098 |
| 24-04-24 | 137.6 | +0.62% | 1,566,638 |
| 24-04-23 | 136.7 | +5.08% | 2,088,321 |
| 24-04-22 | 130.1 | +1.28% | 1,694,278 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotes
Quest Diagnostics is the world's leading provider of diagnostics testing and information service for patients and health professionals. Net sales break down by activity as follows:
- testing and diagnostic services (97.3%): routine clinical testing, gene-based testing and advanced diagnostic and anatomica pathology diagnostic services;
- other (2.7%).
Calendar
2024-07-23
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
135.4
USD
Average target price
146
USD
Spread / Average Target
+7.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.63% | 15.04B | |
| -14.92% | 84.87B | |
| +13.30% | 83.08B | |
| +10.92% | 29.4B | |
| -12.71% | 16.72B | |
| -3.06% | 16.4B | |
| -3.97% | 11.88B | |
| -1.42% | 11.88B | |
| -31.75% | 11.86B | |
| +27.44% | 11.64B |
- Stock Market
- Equities
- DGX Stock
